Therefore, a possible combination therapy of TAM or FULV with radiotherapy for HNSCC patients is observed, since the same study showed that HNSCC cells with combined expression of ESR2 and gene for submaxillary gland androgen-regulated protein 3A (SMR3A) have a higher risk for radiotherapy failure [121]. The gene discussed is SMR3A; the disease is head and neck squamous cell carcinoma.